Literature DB >> 28760899

Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c.

Atica Moosa1, Dirk A Lamprecht2, Kriti Arora3, Clifton E Barry3,4, Helena I M Boshoff3, Thomas R Ioerger5, Adrie J C Steyn2,6,7, Valerie Mizrahi1,4, Digby F Warner8,4.   

Abstract

We deleted subunits I (cydA) and II (cydB) of the Mycobacterium tuberculosis cytochrome bd menaquinol oxidase. The resulting ΔcydA and ΔcydAB mutants were hypersusceptible to compounds targeting the mycobacterial bc1 menaquinol-cytochrome c oxidoreductase and exhibited bioenergetic profiles indistinguishable from strains deficient in the ABC-type transporter, CydDC, predicted to be essential for cytochrome bd assembly. These results confirm CydAB and CydDC as potential targets for drugs aimed at inhibiting a terminal respiratory oxidase implicated in pathogenesis.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  TB drug discovery; electron transport chain; extracellular flux analysis; mycobacterial respiration; oxidative phosphorylation

Mesh：

Substances：

Year:  2017        PMID： 28760899      PMCID： PMC5610507          DOI： 10.1128/AAC.01338-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

2.  Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis.

Authors:  Kriti Arora; Bernardo Ochoa-Montaño; Patricia S Tsang; Tom L Blundell; Stephanie S Dawes; Valerie Mizrahi; Tracy Bayliss; Claire J Mackenzie; Laura A T Cleghorn; Peter C Ray; Paul G Wyatt; Eugene Uh; Jinwoo Lee; Clifton E Barry; Helena I Boshoff
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 3.  The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Gary Maartens; Kelly E Dooley; Ruth McNerney; Megan Murray; Jennifer Furin; Edward A Nardell; Leslie London; Erica Lessem; Grant Theron; Paul van Helden; Stefan Niemann; Matthias Merker; David Dowdy; Annelies Van Rie; Gilman K H Siu; Jotam G Pasipanodya; Camilla Rodrigues; Taane G Clark; Frik A Sirgel; Aliasgar Esmail; Hsien-Ho Lin; Sachin R Atre; H Simon Schaaf; Kwok Chiu Chang; Christoph Lange; Payam Nahid; Zarir F Udwadia; C Robert Horsburgh; Gavin J Churchyard; Dick Menzies; Anneke C Hesseling; Eric Nuermberger; Helen McIlleron; Kevin P Fennelly; Eric Goemaere; Ernesto Jaramillo; Marcus Low; Carolina Morán Jara; Nesri Padayatchi; Robin M Warren
Journal:  Lancet Respir Med       Date:  2017-03-15       Impact factor: 30.700

Review 4.  Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria.

Authors:  Gregory M Cook; Kiel Hards; Catherine Vilchèze; Travis Hartman; Michael Berney
Journal:  Microbiol Spectr       Date:  2014-06

Review 5.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

6.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

Review 7.  Tuberculosis - metabolism and respiration in the absence of growth.

Authors:  Helena I M Boshoff; Clifton E Barry
Journal:  Nat Rev Microbiol       Date:  2005-01       Impact factor: 60.633

8.  Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration.

Authors:  Lanbo Shi; Charles D Sohaskey; Bavesh D Kana; Stephanie Dawes; Robert J North; Valerie Mizrahi; Maria L Gennaro
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-14       Impact factor: 11.205

9.  A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells.

Authors:  Paridhi Sukheja; Pradeep Kumar; Nisha Mittal; Shao-Gang Li; Eric Singleton; Riccardo Russo; Alexander L Perryman; Riju Shrestha; Divya Awasthi; Seema Husain; Patricia Soteropoulos; Roman Brukh; Nancy Connell; Joel S Freundlich; David Alland
Journal:  MBio       Date:  2017-02-14       Impact factor: 7.867

Review 10.  Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery.

Authors:  Dirk Bald; Cristina Villellas; Ping Lu; Anil Koul
Journal:  mBio       Date:  2017-04-11       Impact factor: 7.867
View more
  25 in total

1.  Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase.

Authors:  Amaravadhi Harikishore; Sherilyn Shi Min Chong; Priya Ragunathan; Roderick W Bates; Gerhard Grüber
Journal:  Mol Divers       Date:  2020-01-14       Impact factor: 2.943

2.  Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.

Authors:  Catherine Shelton; Matthew McNeil; Renee Allen; Lindsay Flint; Dara Russell; Bryan Berube; Aaron Korkegian; Yulia Ovechkina; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2022-03-09       Impact factor: 5.191

3.  Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.

Authors:  Colin R Wilson; Richard K Gessner; Atica Moosa; Ronnett Seldon; Digby F Warner; Valerie Mizrahi; Candice Soares de Melo; Sandile B Simelane; Aloysius Nchinda; Efrem Abay; Dale Taylor; Mathew Njoroge; Christel Brunschwig; Nina Lawrence; Helena I M Boshoff; Clifton E Barry; Frederick A Sirgel; Paul van Helden; C John Harris; Richard Gordon; Sonja Ghidelli-Disse; Hannah Pflaumer; Markus Boesche; Gerard Drewes; Olalla Sanz; Gracia Santos; Maria José Rebollo-Lopez; Beatriz Urones; Carolyn Selenski; Maria Jose Lafuente-Monasterio; Matthew Axtman; Joël Lelièvre; Lluis Ballell; Rudolf Mueller; Leslie J Street; Sandeep R Ghorpade; Kelly Chibale
Journal:  J Med Chem       Date:  2017-12-07       Impact factor: 7.446

4.  Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis.

Authors:  Bryan J Berube; Tanya Parish
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd.

Authors:  Ping Lu; Amer H Asseri; Martijn Kremer; Janneke Maaskant; Roy Ummels; Holger Lill; Dirk Bald
Journal:  Sci Rep       Date:  2018-02-08       Impact factor: 4.379

6.  2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization.

Authors:  Dinakaran Murugesan; Peter C Ray; Tracy Bayliss; Gareth A Prosser; Justin R Harrison; Kirsteen Green; Candice Soares de Melo; Tzu-Shean Feng; Leslie J Street; Kelly Chibale; Digby F Warner; Valerie Mizrahi; Ola Epemolu; Paul Scullion; Lucy Ellis; Jennifer Riley; Yoko Shishikura; Liam Ferguson; Maria Osuna-Cabello; Kevin D Read; Simon R Green; Dirk A Lamprecht; Peter M Finin; Adrie J C Steyn; Thomas R Ioerger; Jim Sacchettini; Kyu Y Rhee; Kriti Arora; Clifton E Barry; Paul G Wyatt; Helena I M Boshoff
Journal:  ACS Infect Dis       Date:  2018-03-26       Impact factor: 5.084

7.  Synthesis, Structure-Activity Relationship, and Mechanistic Studies of Aminoquinazolinones Displaying Antimycobacterial Activity.

Authors:  Jessica N Akester; Paul Njaria; Aloysius Nchinda; Claire Le Manach; Alissa Myrick; Vinayak Singh; Nina Lawrence; Mathew Njoroge; Dale Taylor; Atica Moosa; Anthony J Smith; Elizabeth J Brooks; Anne J Lenaerts; Gregory T Robertson; Thomas R Ioerger; Rudolf Mueller; Kelly Chibale
Journal:  ACS Infect Dis       Date:  2020-06-15       Impact factor: 5.084

8.  Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis.

Authors:  Sheng Zeng; Jingran Zhang; Mingwei Sun; Xiaofei Zhang; Gregory M Cook; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

Review 9.  Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.

Authors:  Iram Khan Iqbal; Sapna Bajeli; Ajit Kumar Akela; Ashwani Kumar
Journal:  Pathogens       Date:  2018-02-23

10.  Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.

Authors:  Caroline S Foo; Andréanne Lupien; Maryline Kienle; Anthony Vocat; Andrej Benjak; Raphael Sommer; Dirk A Lamprecht; Adrie J C Steyn; Kevin Pethe; Jérémie Piton; Karl-Heinz Altmann; Stewart T Cole
Journal:  MBio       Date:  2018-10-09       Impact factor: 7.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.